Overview: This document provides an assessment of various immunohistochemistry (IHC) antibodies used in cancer diagnostics, evaluated by NordiQC. The antibodies are ranked based on their performance in specific cancer types.
Specifications: The document lists several IHC antibodies, including CD56, Progesterone Receptor, HER2/neu, CD15, CDX-2, Estrogen Receptor, and MSH6, each associated with different cancer types such as neuroendocrine tumors, breast cancer, Hodgkin’s lymphoma, and colon cancer.
Performance Ratings: The antibodies are rated as 'Optimal' or 'Good' based on their performance in specific runs (RUN 61 and B31). For example, CD56 on neuroendocrine tumors and CDX-2 on colon cancer are rated 'Optimal'.
Quality Assurance: The antibodies are designed and manufactured in-house by GenomeMe, adhering to ISO 13485:2016 and MDSAP quality assurance standards.
Recommendations: For high-quality and cost-effective IHC antibodies, GenomeMe is recommended. Interested parties are encouraged to contact GenomeMe for full NordiQC assessment reports.
Contact Information: For further details, GenomeMe can be contacted via email at
[email protected] or through their website www.GenomeMe.ca/IHC-Antibodies.
See more